贝伐单抗治疗肺癌脑转移的疗效分析

Effects of Bevacizumab on Brain Metastasis of Lung Cancer

目的探讨贝伐单抗治疗肺癌脑转移的临床效果。方法选取我院治疗的肺癌脑转移患者60例作为研究对象,根据治疗方法的不同分为对照组与观察组,对照组采用放疗的治疗方法,观察组采用放疗联合贝伐单抗药物治疗,对比观察两组患者的近期疗效、药物安全性(不良反应)、肌力评分、生存率和脑水肿改善情况。结果治疗后观察组患者的治疗有效率高于对照组(P<0.05);治疗前两组患者的肌力评分无显著差异(P>0.05),治疗后在肌力评分方面,观察组患者评分明显高于对照组(P<0.05);治疗后观察组患者的不良反应总发生率明显高于对照组,其中高血压、鼻出血的发生率高于对照组(P<0.05);观察组患者的1年、3年、5年生存率显著高于对照组(P<0.05);治疗前两组患者的瘤周水肿和瘤体体积无显著差异,治疗后观察组患者的瘤周水肿及瘤体体积明显减小(P<0.05)。结论贝伐单抗应用治疗肺癌脑转移,临床效果理想,具有安全性、可实施性,应在临床中推广应用。

Objective To investigate the clinical effects of bevacizumab in the treatment of brain metastases of lung cancer. Methods Sixty patients with brain metastases from lung cancer treated by our hospital were selected as the research subjects. According to the different treatment methods, they were divided into two groups. The control group was treated with radiotherapy. The observation group was treated with radiotherapy combined with bevacizumab. The efficacy of the two groups, the drug safety (adverse reaction), muscle strength score, survival rate and improvement of brain edema were observed and compared. Results After treatment, the effective rate of the observation group was higher than that of the control group (P<0.05). There was no significant difference in muscle strength score between the two groups before treatment (P>0.05). After treatment, the muscle strength score of the observation group was significantly higher than that of the control group (P<0.05). The total incidence of adverse reactions in the observation group after treatment was higher than that of the control group. In the observation group, the incidence of hypertension and nasal bleeding was higher than that of the control group (P<0.05). The 1-, 3-, and 5-year survival rates of the patients in the observation group were significantly higher than those in the control group (P<0.05). There was no significant difference in the peritumoral edema and the volume of the tumor body between two groups before treatment. After the treatment, the edema and volume of the tumor body in observation group were significantly reduced (P<0.05). Conclusion Bevacizumab is a safe and effective method for the treatment of brain metastases from lung cancer. It could be widely applied in clinical practice.